Date: 2022-03-30
Type of information: Loan
Company: Vectivbio (Switzerland)
Investors: Kreos Capital (UK)
Amount: up to a $75 million
Funding type: loan
Planned used:
Others: * On March 30, 2022, VectivBio, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, has entered into a loan facility with Kreos Capital, a leading global growth lender to life sciences and healthcare companies, granting it access of up to a $75 million flexible loan facility with a minimum required drawdown of $10 million.
Therapeutic area: Inflammatory diseases - Gastrointestinal diseases - Transplantation
Is general: Yes